

Global Vaccine Market Size study, by Type (Subunit, mRNA), Route of Administration (Oral), Disease Indication (HPV, MMR), Age Group (Adult), Distribution Channel, and Regional Forecasts 2022–2032

<https://marketpublishers.com/r/G3BE77500317EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,750.00 (Single User License)

ID: G3BE77500317EN

Abstracts

Global Vaccine Market is valued approximately at USD 76.08 billion in 2023 and is anticipated to grow with a compound annual growth rate of more than 5.74% over the forecast period 2024–2032. Vaccines have long been heralded as one of the most cost-effective public health interventions, and their global demand is undergoing a paradigm shift driven by technological innovations, evolving epidemiological patterns, and renewed governmental and institutional efforts post-pandemic. As diseases such as HPV, MMR, and emerging zoonotic threats gain renewed attention, the adoption of next-generation vaccine platforms—including mRNA and subunit technologies—has reshaped how both preventive and therapeutic immunization strategies are developed and deployed. These advances are rapidly transcending traditional injection routes, with oral vaccines gaining prominence for their non-invasive appeal and compliance advantages.

The vaccine development ecosystem is currently undergoing a renaissance, with investments flooding into R&D pipelines for faster-response platforms and broader immunogenic coverage. The global market has witnessed an extraordinary mobilization of capital and regulatory fast-tracking, especially since the COVID-19 era, which has helped institutionalize infrastructure for rapid vaccine production and approval. This shift is particularly evident in the adult segment, as global health campaigns shift focus from pediatric-only immunization models to lifelong immunity and booster strategies. Furthermore, the expansion of vaccination programs through retail, digital, and mobile channels has created a seamless distribution mesh, helping reach under-vaccinated and remote populations with minimal lag.

Despite this acceleration, several challenges persist. Misinformation about vaccine safety, geopolitical barriers to cold-chain logistics, and inequitable access in low- and middle-income countries continue to impede the full realization of immunization goals. Moreover, high manufacturing costs of mRNA-based products and complex regulatory pathways delay time-to-market for newer entrants. However, collaborative global partnerships, public-private alliances, and increased deployment of AI in antigen discovery and delivery optimization are addressing these friction points. These innovations not only enhance speed-to-market but also drive personalized vaccine development based on regional strain mutations and population-specific immune responses.

On the innovation frontier, synthetic biology and nanoparticle-based delivery systems are pushing the envelope, promising needle-free administration, thermostable compositions, and broader spectrum protection. Governments and multinational organizations like WHO, Gavi, and CEPI are channeling funds into disease preparedness pipelines, further energizing the vaccine manufacturing ecosystem. Data analytics and wearable tracking devices are also being introduced to monitor patient adherence, immunogenic response, and post-vaccination outcomes, creating feedback loops that refine deployment strategies and support real-world evidence generation.

Regionally, North America maintains its leadership in the vaccine market, backed by robust healthcare systems, early adoption of novel technologies, and heavy investments by companies such as Pfizer and Moderna. Europe trails closely, driven by cohesive vaccination policies, government mandates, and a well-established pharma base. Asia Pacific is poised to emerge as the fastest-growing region, fueled by rising population densities, improving healthcare infrastructure, and large-scale national immunization programs in countries like China, India, and Indonesia. Latin America and Middle East & Africa are registering steady growth through international vaccine collaborations and government-funded health access programs.

Major market player included in this report are:

Pfizer Inc.

GlaxoSmithKline plc

Moderna, Inc.

Sanofi S.A.

Johnson & Johnson

Merck & Co., Inc.

Bharat Biotech International Limited

AstraZeneca plc

Serum Institute of India Pvt. Ltd.

CSL Limited

BioNTech SE

Novavax, Inc.

Emergent BioSolutions Inc.

Vaxart, Inc.

Sinovac Biotech Ltd.

The detailed segments and sub-segment of the market are explained below:

By Type

Subunit

mRNA

By Route of Administration

Oral

By Disease Indication

HPV

MMR

By Age Group

Adult

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with country-level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL VACCINE MARKET EXECUTIVE SUMMARY

- 1.1. Global Vaccine Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Type
 - 1.3.2. By Distribution Channel
- 1.4. Key Trends
- 1.5. Policy & Regulatory Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL VACCINE MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Manufacturing Capacity
 - 2.3.3.2. Cold-Chain Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Competitive Landscape
 - 2.3.3.5. Cost Structures
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Public Health Policies
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Socio-Demographic Trends
 - 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL VACCINE MARKET DYNAMICS

- 3.1. Market Drivers

- 3.1.1. Post-Pandemic Infrastructure and Fast-Track Regulatory Support
- 3.1.2. Rise of Next-Gen Platforms (mRNA, Subunit)
- 3.1.3. Expansion of Adult Immunization and Booster Campaigns
- 3.2. Market Challenges
 - 3.2.1. Vaccine Hesitancy and Misinformation
 - 3.2.2. Cold-Chain and Distribution Barriers in LMICs
- 3.3. Market Opportunities
 - 3.3.1. AI-Driven Antigen Discovery & Delivery Optimization
 - 3.3.2. Oral and Thermostable Vaccine Formulations
 - 3.3.3. Public-Private Partnerships and Global Funding Initiatives

CHAPTER 4. GLOBAL VACCINE MARKET INDUSTRY ANALYSIS

- 4.1. Porter's Five Forces Model
 - 4.1.1. Bargaining Power of Suppliers
 - 4.1.2. Bargaining Power of Buyers
 - 4.1.3. Threat of New Entrants
 - 4.1.4. Threat of Substitutes
 - 4.1.5. Competitive Rivalry
- 4.2. PESTEL Analysis
 - 4.2.1. Political
 - 4.2.2. Economic
 - 4.2.3. Social
 - 4.2.4. Technological
 - 4.2.5. Environmental
 - 4.2.6. Legal
- 4.3. Top Investment Opportunity
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL VACCINE MARKET SIZE & FORECASTS BY TYPE 2022–2032

- 5.1. Segment Dashboard
- 5.2. Vaccine Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
 - 5.2.1. Subunit
 - 5.2.2. mRNA

CHAPTER 6. GLOBAL VACCINE MARKET SIZE & FORECASTS BY ROUTE OF ADMINISTRATION 2022–2032

6.1. Segment Dashboard

6.2. Vaccine Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)

6.2.1. Oral

CHAPTER 7. GLOBAL VACCINE MARKET SIZE & FORECASTS BY REGION 2022–2032

7.1. North America Vaccine Market

7.1.1. U.S. Vaccine Market

7.1.1.1. Type breakdown size & forecasts, 2022–2032

7.1.1.2. Distribution Channel breakdown size & forecasts, 2022–2032

7.1.2. Canada Vaccine Market

7.2. Europe Vaccine Market

7.2.1. UK Vaccine Market

7.2.2. Germany Vaccine Market

7.2.3. France Vaccine Market

7.2.4. Spain Vaccine Market

7.2.5. Italy Vaccine Market

7.2.6. Rest of Europe Vaccine Market

7.3. Asia Pacific Vaccine Market

7.3.1. China Vaccine Market

7.3.2. India Vaccine Market

7.3.3. Japan Vaccine Market

7.3.4. Australia Vaccine Market

7.3.5. South Korea Vaccine Market

7.3.6. Rest of Asia Pacific Vaccine Market

7.4. Latin America Vaccine Market

7.4.1. Brazil Vaccine Market

7.4.2. Mexico Vaccine Market

7.4.3. Rest of Latin America Vaccine Market

7.5. Middle East & Africa Vaccine Market

7.5.1. Saudi Arabia Vaccine Market

7.5.2. South Africa Vaccine Market

7.5.3. Rest of Middle East & Africa Vaccine Market

CHAPTER 8. COMPETITIVE INTELLIGENCE

8.1. Key Company SWOT Analysis

8.1.1. Pfizer Inc.

8.1.2. Moderna, Inc.

8.1.3. GlaxoSmithKline plc

8.2. Top Market Strategies

8.3. Company Profiles

8.3.1. Pfizer Inc.

8.3.1.1. Key Information

8.3.1.2. Overview

8.3.1.3. Financial (Subject to Data Availability)

8.3.1.4. Product Summary

8.3.1.5. Market Strategies

8.3.2. Moderna, Inc.

8.3.3. GlaxoSmithKline plc

8.3.4. Sanofi S.A.

8.3.5. Johnson & Johnson

8.3.6. Merck & Co., Inc.

8.3.7. Bharat Biotech International Limited

8.3.8. AstraZeneca plc

8.3.9. Serum Institute of India Pvt. Ltd.

8.3.10. CSL Limited

8.3.11. BioNTech SE

8.3.12. Novavax, Inc.

8.3.13. Emergent BioSolutions Inc.

8.3.14. Vaxart, Inc.

8.3.15. Sinovac Biotech Ltd.

CHAPTER 9. RESEARCH PROCESS

9.1. Research Process

9.1.1. Data Mining

9.1.2. Analysis

9.1.3. Market Estimation

9.1.4. Validation

9.1.5. Publishing

9.2. Research Attributes

I would like to order

Product name: Global Vaccine Market Size study, by Type (Subunit, mRNA), Route of Administration (Oral), Disease Indication (HPV, MMR), Age Group (Adult), Distribution Channel, and Regional Forecasts 2022–2032

Product link: <https://marketpublishers.com/r/G3BE77500317EN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3BE77500317EN.html>